Myocardial Tissue Characterization Using Magnetic Resonance Noncontrast T1 Mapping in Hypertrophic and Dilated Cardiomyopathy

Background—Noncontrast magnetic resonance T1 mapping reflects a composite of both intra- and extracellular signal. We hypothesized that noncontrast T1 mapping can characterize the myocardium beyond that achieved by the well-established late gadolinium enhancement (LGE) technique (which detects focal fibrosis) in both hypertrophic (HCM) and dilated (DCM) cardiomyopathy, by detecting both diffuse and focal fibrosis. Methods and Results—Subjects underwent Cardiovascular Magnetic Resonance imaging at 3T (28 HCM, 18 DCM, and 12 normals). Matching short-axis slices were acquired for cine, T1 mapping, and LGE imaging (0.1 mmol/kg). Circumferential strain was measured in the midventricular slice, and 31P magnetic resonance spectroscopy was acquired for the septum of the midventricular slice. Mean T1 relaxation time was increased in HCM and DCM (HCM 1209±28 ms, DCM 1225±42 ms, normal 1178±13 ms, P<0.05). There was a weak correlation between mean T1 and LGE (r=0.32, P<0.001). T1 values were higher in segments with LGE than in those without (HCM with LGE 1228±41 ms versus no LGE 1192±79 ms, P<0.01; DCM with LGE 1254±73 ms versus no LGE 1217±52 ms, P<0.01). However, in both HCM and DCM, even in segments unaffected by LGE, T1 values were significantly higher than normal (P<0.01). T1 values correlated with disease severity, being increased as wall thickness increased in HCM; conversely, in DCM, T1 values were highest in the thinnest myocardial segments. T1 values also correlated significantly with circumferential strain (r=0.42, P<0.01). Interestingly, this correlation remained statistically significant even for the slices without LGE (r=0.56, P=0.04). Finally, there was also a statistically significant negative correlation between T1 values and phosphocreatine/adenosine triphosphate ratios (r=−0.59, P<0.0001). Conclusions—In HCM and DCM, noncontrast T1 mapping detects underlying disease processes beyond those assessed by LGE in relatively low-risk individuals.

[1]  A. Flett,et al.  Characterising the myocardial interstitial space: the clinical relevance of non-invasive imaging , 2012, Heart.

[2]  杜昕,et al.  Inherited cardiomyopathies , 2012 .

[3]  S. K. White,et al.  Age and gender dependence of pre-contrast T1-relaxation times in normal human myocardium at 1.5T using ShMOLLI , 2012, Journal of Cardiovascular Magnetic Resonance.

[4]  S. Neubauer,et al.  Exercise Acutely Exacerbates Derangement Of Cardiac Energy Metabolism In Hypertrophic Cardiomyopathy, a 31 Phosphorus Magnetic Resonance Study at 3 Telsa , 2011 .

[5]  M. Pasque,et al.  Magnetic resonance imaging detects significant sex differences in human myocardial strain , 2011, Biomedical engineering online.

[6]  Pierre Croisille,et al.  Assessment of myocardial fibrosis with cardiovascular magnetic resonance. , 2011, Journal of the American College of Cardiology.

[7]  Vivek Muthurangu,et al.  Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. , 2011, JACC. Cardiovascular imaging.

[8]  M. Cheitlin,et al.  Myocardial Scar Visualized by Cardiovascular Magnetic Resonance Imaging Predicts Major Adverse Events in Patients With Hypertrophic Cardiomyopathy , 2011 .

[9]  H. Watkins,et al.  Inherited cardiomyopathies. , 2011, The New England journal of medicine.

[10]  Stefan Neubauer,et al.  Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold , 2010, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance.

[11]  B. Byrne,et al.  Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute. , 2010, Circulation.

[12]  S. Colan,et al.  Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. , 2010, The New England journal of medicine.

[13]  M. Hayward,et al.  Equilibrium Contrast Cardiovascular Magnetic Resonance for the Measurement of Diffuse Myocardial Fibrosis: Preliminary Validation in Humans , 2010, Circulation.

[14]  M. Sheppard,et al.  Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy using cardiovascular magnetic resonance , 2010 .

[15]  A. Tajik,et al.  Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy , 2010, Circulation. Heart failure.

[16]  M. Robson,et al.  Reproducibility of 31P cardiac magnetic resonance spectroscopy at 3 T , 2009, NMR in biomedicine.

[17]  Sandeep N. Gupta,et al.  Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. , 2008, Journal of the American College of Cardiology.

[18]  D. Graveron-Demilly,et al.  Java-based graphical user interface for the MRUI quantitation package , 2001, Magnetic Resonance Materials in Physics, Biology and Medicine.

[19]  Dudley J Pennell,et al.  Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[20]  Christine E Seidman,et al.  A Contemporary Approach to Hypertrophic Cardiomyopathy , 2006, Circulation.

[21]  David C. Sheridan,et al.  Resting Myocardial Blood Flow Is Impaired in Hibernating Myocardium: A Magnetic Resonance Study of Quantitative Perfusion Assessment , 2005, Circulation.

[22]  Stefan Neubauer,et al.  Ultrashort TE chemical shift imaging (UTE‐CSI) , 2005, Magnetic resonance in medicine.

[23]  Erik G. Ellsworth,et al.  Prevalence and Spectrum of Thin Filament Mutations in an Outpatient Referral Population With Hypertrophic Cardiomyopathy , 2003, Circulation.

[24]  A. Blamire,et al.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. , 2003, Journal of the American College of Cardiology.

[25]  D. Pennell,et al.  Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. , 2003, Journal of the American College of Cardiology.

[26]  P. Elliott,et al.  Role of genotyping in risk factor assessment for sudden death in hypertrophic cardiomyopathy. , 2002, Journal of the American College of Cardiology.

[27]  J. Towbin,et al.  The failing heart , 2002, Nature.

[28]  U Ravens,et al.  Task Force on Sudden Cardiac Death of the European Society of Cardiology. , 2001, European heart journal.

[29]  R. de Beer,et al.  Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals , 2001, Comput. Biol. Medicine.

[30]  R Pohmann,et al.  Accurate phosphorus metabolite images of the human heart by 3D acquisition‐weighted CSI , 2001, Magnetic resonance in medicine.

[31]  C. Brilla,et al.  Lisinopril-Mediated Regression of Myocardial Fibrosis in Patients With Hypertensive Heart Disease , 2000, Circulation.

[32]  B. Strauer,et al.  Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. , 2000, Hypertension.

[33]  J. Gardin,et al.  Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. , 1995, Circulation.

[34]  M. Laser,et al.  Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. , 1995, The Journal of clinical investigation.

[35]  P A Bottomley,et al.  Optimum flip‐angles for exciting NMR with uncertain T1 values , 1994, Magnetic resonance in medicine.

[36]  S. Neubauer,et al.  31P Magnetic Resonance Spectroscopy in Dilated Cardiomyopathy and Coronary Artery Disease: Altered Cardiac High‐Energy Phosphate Metabolism in Heart Failure , 1992, Circulation.

[37]  K. Weber,et al.  Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System , 1991, Circulation.